Lymphoma Study Group of JCOG

Tsukasaki, Kunihiro; Tobinai, Kensei; Hotta, T; Shimoyama, Masanori

doi:10.1093/jjco/hyr168

Cited by 23 publications

(16 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Mortality trends related to liver cancer appeared favorable in women from both the provinces of interest. Liver cancer incidence rates recorded in southern Italy are among the highest all over Europe and are mostly attributable to HBV and/or HCV infections.…”

Section: Discussionmentioning

confidence: 99%

Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy

Crispo¹,

Barba²,

Malvezzi³

et al. 2013

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy

Crispo¹,

Barba²,

Malvezzi³

et al. 2013

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Therapy for intraocular infiltration previously relied on systemic ATL therapy such as intensive multi-agent chemotherapy (Tsukasaki et al, 2012), interferon-a combined with zidovudine (Gill et al, 1995), anti-CCR4 antibody (mogamulizumab) (Ishida et al, 2012), hematopoietic stem cell transplantation (Zell et al, 2016), and Tax peptide-pulsed dendritic cell vaccine (Suehiro et al, 2015). These advanced therapies are considered effective for ATL ocular infiltration.…”

Section: Infiltrationmentioning

confidence: 99%

HTLV-1 in Ophthalmology

Kamoi

2020

Front. Microbiol.

View full text Add to dashboard Cite

Human T-cell leukemia virus type 1 (HTLV-1) was the first retrovirus described as a causative agent for human disease. In the field of ophthalmology, a close relationship between HTLV-1 infection and uveitis was identified through a series of clinical and laboratory studies in the late 1980s-1990s. Since then, HTLV-1-related ocular manifestations such as keratoconjunctivitis sicca, interstitial keratitis, optic neuritis and adult T-cell leukemia/lymphoma (ATL)-related ocular manifestations have continuously been reported. During the three decades since the association between HTLV-1 and ocular pathologies was discovered, ophthalmic practice and research have advanced with the incorporation of new technologies into the field of ophthalmology. Accordingly, new findings from recent research have provided many insights into HTLV-1-associated ocular diseases. Advanced molecular technologies such as multiplex polymerase chain reaction (PCR)/broad-range PCR using ocular samples have enabled rapid and accurate diagnosis. Advanced ophthalmic technologies such as widefield fundus camera and optical coherence tomography (OCT) have clarified various features of HTLV-1-associated ocular manifestations, and identified characteristics such as the "knob-like ATL cell multiple ocular infiltration" (KAMOI) sign. Advanced drug delivery methods such as intravitreal injection and sub-Tenon injection have led to progress in preventing disease progression. This article describes global topics and the latest research findings for HTLV-1-associated ocular diseases, with reference to a largescale nationwide survey of ophthalmologists. Current approaches and unmet needs for HTLV-1 infection in ophthalmology are also discussed.

show abstract

“…The disappointing results with conventional CHOP‐like chemotherapies in the 1980s and the proposal for a subtype classification of ATL have led to a search for new active treatments against aggressive ATL (Table ) . In the 1990s, a phase II trial (JCOG9303) was conducted to investigate a multiagent chemotherapeutic regimen (LSG15; VCAP‐AMP‐VECP) consisting of vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP); doxorubicin, ranimustine, and prednisone (AMP); and vindesine, etoposide, carboplatin, and prednisone (VECP), intensified with the prophylactic use of granulocyte‐colony stimulating factor (G‐CSF).…”

Section: Disease‐oriented Treatment Of Atlmentioning

confidence: 99%

“…7 Table 2). 8 In the 1990s, a phase II trial (JCOG9303) was conducted to investigate a multiagent chemotherapeutic regimen (LSG15; VCAP-AMP-VECP) consisting of vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP); doxorubicin, ranimustine, and prednisone (AMP); and vindesine, etoposide, carboplatin, and prednisone (VECP), intensified with the prophylactic use of granulocyte-colony stimulating factor (G-CSF). Because central nervous system involvement occurs in 10% to 20% of patients with ATL, intrathecal prophylaxis was incorporated.…”

Section: Disease-oriented Treatment Of Enklmentioning

confidence: 99%